688065 凯赛生物
已收盘 06-23 15:00:01
资讯
新帖
简况
股市必读：凯赛生物（688065）6月22日董秘有最新回复
证券之星 · 06-23 04:01
股市必读：凯赛生物（688065）6月22日董秘有最新回复
凯赛生物：基于生物基热塑性复合材料可在机器人关节、骨架等部件应用
证券之星 · 06-22 15:37
凯赛生物：基于生物基热塑性复合材料可在机器人关节、骨架等部件应用
凯赛生物：生物基聚酰胺复合材料在光伏边框领域的应用在进行不同工艺的产品开发和测试验证
证券之星 · 06-22 15:36
凯赛生物：生物基聚酰胺复合材料在光伏边框领域的应用在进行不同工艺的产品开发和测试验证
凯赛生物：股份回购需综合考虑资金安排、资本开支及监管要求等因素
证券之星 · 06-22 15:36
凯赛生物：股份回购需综合考虑资金安排、资本开支及监管要求等因素
凯赛生物：上述两个项目的产品定位与应用方向有所不同
证券之星 · 06-22 15:36
凯赛生物：上述两个项目的产品定位与应用方向有所不同
股市必读：凯赛生物（688065）6月18日董秘有最新回复
证券之星 · 06-22 02:40
股市必读：凯赛生物（688065）6月18日董秘有最新回复
每周股票复盘：凯赛生物（688065）董事会秘书变更
证券之星 · 06-20
每周股票复盘：凯赛生物（688065）董事会秘书变更
凯赛生物（688065）披露关于变更持续督导保荐代表人的公告，6月18日股价上涨2.88%
证券之星 · 06-18
凯赛生物（688065）披露关于变更持续督导保荐代表人的公告，6月18日股价上涨2.88%
凯赛生物：秸秆高值化利用是公司非粮原料产业化研发和布局的重要方向
证券之星 · 06-18
凯赛生物：秸秆高值化利用是公司非粮原料产业化研发和布局的重要方向
凯赛生物（688065）披露董事会秘书变更公告，6月16日股价下跌3.05%
证券之星 · 06-16
凯赛生物（688065）披露董事会秘书变更公告，6月16日股价下跌3.05%
凯赛生物跌3.05% 2020年上市即巅峰2度募资合计115亿
中金财经 · 06-16
凯赛生物跌3.05% 2020年上市即巅峰2度募资合计115亿
凯赛生物：2026年6月25日召开2025年年度股东会
证券日报网 · 06-04
凯赛生物：2026年6月25日召开2025年年度股东会
每周股票复盘：凯赛生物（688065）2025年营收增11.40%
证券之星 · 05-24
每周股票复盘：凯赛生物（688065）2025年营收增11.40%
凯赛生物（688065）披露2025年度持续督导工作现场检查报告，5月21日股价下跌4.03%
证券之星 · 05-21
凯赛生物（688065）披露2025年度持续督导工作现场检查报告，5月21日股价下跌4.03%
凯赛生物（688065）发布2025年度持续督导跟踪报告，5月20日股价上涨1.78%
证券之星 · 05-20
凯赛生物（688065）发布2025年度持续督导跟踪报告，5月20日股价上涨1.78%
凯赛生物跌2.38% 2020年上市即巅峰2度募资合计115亿
中金财经 · 05-15
凯赛生物跌2.38% 2020年上市即巅峰2度募资合计115亿
年收破30亿 凯赛生物(688065.SH)是否真稀缺标的？
智通财经 · 05-09
年收破30亿 凯赛生物(688065.SH)是否真稀缺标的？
股市必读：凯赛生物一季报 - 第一季度单季净利润同比增长21.01%
证券之星 · 05-06
股市必读：凯赛生物一季报 - 第一季度单季净利润同比增长21.01%
每周股票复盘：凯赛生物（688065）现折价21.99%大宗交易
证券之星 · 05-02
每周股票复盘：凯赛生物（688065）现折价21.99%大宗交易
凯赛生物（688065）2026年一季报简析：营收净利润同比双双增长，三费占比上升明显
证券之星 · 05-01
凯赛生物（688065）2026年一季报简析：营收净利润同比双双增长，三费占比上升明显
加载更多
公司概况
公司名称：
上海凯赛生物技术股份有限公司
所属行业：
化学纤维制造业
上市日期：
2020-08-12
主营业务：
上海凯赛生物技术股份有限公司的主营业务是新型生物基材料的研发、生产及销售。公司的主要产品是系列生物法长链二元酸（DC10-DC18）、生物基戊二胺、系列生物基聚酰胺、生物基连续纤维热塑型复合材料（Bio-PPACFRT）。截至报告期末，公司拥有434项发明专利在内的562项专利，被认定为“国家企业技术中心”、“国家级第三批专精特新‘小巨人’企业”、“国家知识产权局优势企业”、“国家绿色工厂”、“国家制造业单项冠军企业”。
发行价格：
133.45
{"stockData":{"symbol":"688065","market":"SH","secType":"STK","nameCN":"凯赛生物","latestPrice":51,"timestamp":1782198001000,"preClose":50.7,"halted":0,"volume":12228615,"delay":0,"changeRate":0.0059,"floatShares":583000000,"shares":721000000,"eps":0.8173,"marketStatus":"已收盘","change":0.3,"latestTime":"06-23 15:00:01","open":50.2,"high":51.95,"low":49.39,"amount":623000000,"amplitude":0.0505,"askPrice":51.05,"askSize":2,"bidPrice":51,"bidSize":22,"shortable":0,"etf":0,"ttmEps":0.8173,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782264600000},"marketStatusCode":5,"adr":0,"adjPreClose":50.7,"symbolType":"stock_kcb","openAndCloseTimeList":[[1782178200000,1782185400000],[1782190800000,1782198000000]],"highLimit":55.77,"lowLimit":45.63,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":721289794,"isCdr":false,"pbRate":2.06,"roa":"--","peRate":62.400587,"roe":"0.93%","epsLYR":0.82,"committee":0.235955,"marketValue":36786000000,"turnoverRate":0.021,"status":0,"afterMarket":{"amount":0,"volume":0,"close":51,"buyVolume":0,"sellVolume":0,"time":1782200037746,"indexStatus":"已收盘 06-23 15:30:00","preClose":50.7},"floatMarketCap":29752000000},"requestUrl":"/m/hq/s/688065","defaultTab":"news","newsList":[{"id":"2645077113","title":"股市必读：凯赛生物（688065）6月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645077113","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645077113?lang=zh_cn&edition=full","pubTime":"2026-06-23 04:01","pubTimestamp":1782158519,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘，凯赛生物报收于50.7元，上涨14.47%，换手率2.78%，成交量16.22万手，成交额7.74亿元。董秘最新回复投资者： 你好，贵公司产品在人形机器人和其他机器人领域是否有应用？公司高度重视股东回报，并持续关注股价表现。股份回购需综合考虑资金安排、资本开支及监管要求等因素，如有相关计划，公司将严格按照规定履行信息披露义务。当日关注点交易信息汇总：6月22日主力资金净流入32.99万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300003883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645044714","title":"凯赛生物：基于生物基热塑性复合材料可在机器人关节、骨架等部件应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2645044714","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645044714?lang=zh_cn&edition=full","pubTime":"2026-06-22 15:37","pubTimestamp":1782113862,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物(688065)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，贵公司产品在人形机器人和其他机器人领域是否有应用？未来在机器人方向应用空间？谢谢凯赛生物回复：尊敬的投资者，您好。基于凯赛生物基热塑性复合材料的优异性能，可以在机器人的关节、骨架、外壳、电池壳体以及轴承等部件应用，为机器人带来高强度、轻量化、耐疲劳以及环保性等核心价值。目前公司产品已经给客户送样。感谢您的关注与支持。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200016807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645044241","title":"凯赛生物：生物基聚酰胺复合材料在光伏边框领域的应用在进行不同工艺的产品开发和测试验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2645044241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645044241?lang=zh_cn&edition=full","pubTime":"2026-06-22 15:36","pubTimestamp":1782113780,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物(688065)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在去年业绩说明会上提到“光伏边框”正在进行TUV认证，一年过去了，到现在这个认证进展到什么程度了？在今年的业绩说明会互动交流中，公司提到光伏边框正在进行示范项目的产能建设，能具体介绍下这个事的情况吗凯赛生物回复：尊敬的投资者，您好。公司生物基聚酰胺复合材料在光伏边框领域的应用在进行不同工艺的产品开发和测试验证，并计划联合战略合作方推进应用示范项目的产能建设。感谢您的关注与支持。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200016579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645604478","title":"凯赛生物：股份回购需综合考虑资金安排、资本开支及监管要求等因素","url":"https://stock-news.laohu8.com/highlight/detail?id=2645604478","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645604478?lang=zh_cn&edition=full","pubTime":"2026-06-22 15:36","pubTimestamp":1782113779,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物(688065)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价上市即巅峰，严重破发，为什么公司不大幅度回购以提振投资者信心。凯赛生物回复：尊敬的投资者，您好。公司高度重视股东回报，并持续关注股价表现。股份回购需综合考虑资金安排、资本开支及监管要求等因素，如有相关计划，公司将严格按照规定履行信息披露义务。感谢您的关注与支持。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200016577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645044206","title":"凯赛生物：上述两个项目的产品定位与应用方向有所不同","url":"https://stock-news.laohu8.com/highlight/detail?id=2645044206","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645044206?lang=zh_cn&edition=full","pubTime":"2026-06-22 15:36","pubTimestamp":1782113779,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物06月22日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，公司在2024年年报里就已提到乌苏年产2万吨长链聚酰胺已结项，但在2025年里一直没有产能和销售营收的贡献。想问，这个新建的长链尼龙和2023年结项的2万吨长链聚酰胺是相同的产品吗？公司基于产品特点和市场需求综合规划产品线布局，上述两个项目的产品定位与应用方向有所不同。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200016576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645155390","title":"股市必读：凯赛生物（688065）6月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645155390","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645155390?lang=zh_cn&edition=full","pubTime":"2026-06-22 02:40","pubTimestamp":1782067220,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，凯赛生物报收于44.29元，上涨2.88%，换手率1.09%，成交量6.37万手，成交额2.83亿元。公司公告汇总关于变更持续督导保荐代表人的公告上海凯赛生物技术股份有限公司接到中信证券通知，原持续督导保荐代表人孟夏先生因工作安排不再负责公司持续督导工作；中信证券委派邵荣圣先生接替其职务，继续履行持续督导职责。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200000947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644063106","title":"每周股票复盘：凯赛生物（688065）董事会秘书变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2644063106","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644063106?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:15","pubTimestamp":1781892913,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，凯赛生物报收于44.29元，较上周的45.22元下跌2.06%。本周，凯赛生物6月15日盘中最高价报46.39元。本周关注点公司公告汇总：董事会秘书由臧慧卿变更为郑倩，臧慧卿仍任副董事长等职。同日，公司第三届董事会第十次会议审议通过聘任郑倩女士为新任董事会秘书，任期与第三届董事会一致。郑倩女士具备任职资格，已取得科创板董事会秘书资格证书。公司董事会对孟夏先生在持续督导期间的贡献表示感谢。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644084808","title":"凯赛生物（688065）披露关于变更持续督导保荐代表人的公告，6月18日股价上涨2.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644084808","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644084808?lang=zh_cn&edition=full","pubTime":"2026-06-18 22:27","pubTimestamp":1781792835,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，凯赛生物报收于44.29元，较前一交易日上涨2.88%，最新总市值为319.46亿元。近日，上海凯赛生物技术股份有限公司披露《关于变更持续督导保荐代表人的公告》。公告显示，公司接到中信证券通知，原持续督导保荐代表人孟夏先生因工作安排不再负责公司持续督导工作；中信证券委派邵荣圣先生接替其职务，继续履行持续督导职责。公司董事会对孟夏先生在持续督导期间的贡献表示感谢。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800042572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644970226","title":"凯赛生物：秸秆高值化利用是公司非粮原料产业化研发和布局的重要方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2644970226","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644970226?lang=zh_cn&edition=full","pubTime":"2026-06-18 18:24","pubTimestamp":1781778251,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物(688065)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：您好：请问公司的万吨级的秸秆高值化利用项目进展如何？进入中试阶段了吗？转化率多高？谢谢！凯赛生物回复：尊敬的投资者，您好。秸秆高值化利用是公司非粮原料产业化研发和布局的重要方向，公司持续关注秸秆综合利用的技术和产业趋势，并正在考察合适的项目落地地点和商业可行性，相关工作正按计划推进。感谢您的关注与支持。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800032834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643763308","title":"凯赛生物（688065）披露董事会秘书变更公告，6月16日股价下跌3.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643763308","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643763308?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:16","pubTimestamp":1781619382,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，凯赛生物报收于43.51元，较前一交易日下跌3.05%，最新总市值为313.83亿元。该股当日开盘44.6元，最高44.75元，最低43.4元，成交额达2.19亿元，换手率为0.86%。近日，上海凯赛生物技术股份有限公司发布《关于董事会秘书变更的公告》。同日，公司第三届董事会第十次会议审议通过聘任郑倩女士为新任董事会秘书，任期与第三届董事会一致。郑倩女士具备任职资格，已取得科创板董事会秘书资格证书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600044089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643973739","title":"凯赛生物跌3.05% 2020年上市即巅峰2度募资合计115亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2643973739","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643973739?lang=zh_cn&edition=full","pubTime":"2026-06-16 16:20","pubTimestamp":1781598002,"startTime":"0","endTime":"0","summary":"中国经济网北京6月16日讯 凯赛生物 今日收报43.51元，跌幅3.05%。 凯赛生物于2020年8月12日在上交所科创板上市，公开发行股份总数为4,166.8198万股，占发行后股份总数的10.00%，发行价格为133.45元/股，保荐人为中信证券股份有限公司，保荐代表人为先卫国、黄艺彬。 上市首日，凯赛生物盘中最高价198元，为该股上市以来最高价。 凯赛生物首次公开发行股票募集资金总额556,062.10万元，募集资金净额为527,999.38万元。 凯赛生物上述2次募集资金合计114.87亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260616/32281209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640163077","title":"凯赛生物：2026年6月25日召开2025年年度股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2640163077","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640163077?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:02","pubTimestamp":1780581720,"startTime":"0","endTime":"0","summary":"证券日报网讯6月4日，凯赛生物发布公告称，公司将于2026年6月25日召开2025年年度股东会。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-04/doc-iniahhrh3414351.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-04/doc-iniahhrh3414351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637486373","title":"每周股票复盘：凯赛生物（688065）2025年营收增11.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637486373","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637486373?lang=zh_cn&edition=full","pubTime":"2026-05-24 02:41","pubTimestamp":1779561669,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，凯赛生物报收于43.46元，较上周的45.88元下跌5.27%。本周，凯赛生物5月21日盘中最高价报46.07元。中信证券作为保荐人，发布凯赛生物2025年度持续督导跟踪报告，报告期内公司实现营业收入329,505.19万元，同比增长11.40%；净利润56,072.00万元，同比增长14.68%。中信证券对凯赛生物开展2025年度持续督导工作现场检查，涵盖公司治理、信息披露、募集资金使用、关联交易、对外担保、重大对外投资等方面。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637332348","title":"凯赛生物（688065）披露2025年度持续督导工作现场检查报告，5月21日股价下跌4.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637332348","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637332348?lang=zh_cn&edition=full","pubTime":"2026-05-21 22:22","pubTimestamp":1779373341,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，凯赛生物报收于43.29元，较前一交易日下跌4.03%，最新总市值为312.25亿元。近日，中信证券股份有限公司发布《关于上海凯赛生物技术股份有限公司2025年度持续督导工作现场检查报告》。公告显示，中信证券作为保荐人，对凯赛生物2025年度持续督导期间的规范运作情况进行了现场检查，涵盖公司治理、信息披露、募集资金使用、关联交易、对外担保、重大对外投资等方面。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100044449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636772845","title":"凯赛生物（688065）发布2025年度持续督导跟踪报告，5月20日股价上涨1.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636772845","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636772845?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:29","pubTimestamp":1779272953,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，凯赛生物报收于45.11元，较前一交易日上涨1.78%，最新总市值为325.37亿元。该股当日开盘43.97元，最高45.42元，最低43.61元，成交额达2.57亿元，换手率为0.99%。近日，中信证券股份有限公司发布《关于上海凯赛生物技术股份有限公司2025年度持续督导跟踪报告》。公告显示，报告期内，公司营业收入329,505.19万元，同比增长11.40%；净利润56,072.00万元，同比增长14.68%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000035742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635701969","title":"凯赛生物跌2.38% 2020年上市即巅峰2度募资合计115亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2635701969","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635701969?lang=zh_cn&edition=full","pubTime":"2026-05-15 15:57","pubTimestamp":1778831820,"startTime":"0","endTime":"0","summary":"中国经济网北京5月15日讯 凯赛生物 今日收报45.88元，跌幅2.38%。 凯赛生物于2020年8月12日在上交所科创板上市，公开发行股份总数为4,166.8198万股，占发行后股份总数的10.00%，发行价格为133.45元/股，保荐人为中信证券股份有限公司，保荐代表人为先卫国、黄艺彬。 上市首日，凯赛生物盘中最高价198元，为该股上市以来最高价。 凯赛生物首次公开发行股票募集资金总额556,062.10万元，募集资金净额为527,999.38万元。 凯赛生物上述2次募集资金合计114.87亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260515/32227644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0208","688065","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634049750","title":"年收破30亿 凯赛生物(688065.SH)是否真稀缺标的？","url":"https://stock-news.laohu8.com/highlight/detail?id=2634049750","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634049750?lang=zh_cn&edition=full","pubTime":"2026-05-09 15:58","pubTimestamp":1778313487,"startTime":"0","endTime":"0","summary":"随着2026年4月年报披露季结束，在生物科技赛道共计134家上市公司中，以收入规模增速、净利润增速、毛利率增速等指标均为正增长为筛选标准，凯赛生物成为率先用三年时间验证产业化平台模式的企业，实现了从合成生物学概念兴起到生物制造被定位为国家未来支柱产业进程中的阶段性突破。其中在3家公司总资产均处在增长阶段的背景下，仅凯赛生物营收规模突破30亿，也只有凯赛生物连续三年毛利率稳步提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439863.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633921823","title":"股市必读：凯赛生物一季报 - 第一季度单季净利润同比增长21.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633921823","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633921823?lang=zh_cn&edition=full","pubTime":"2026-05-06 04:23","pubTimestamp":1778012589,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，凯赛生物报收于48.11元，上涨0.78%，换手率1.37%，成交量7.97万手，成交额3.89亿元。来自业绩披露要点：2026年一季度归母净利润同比增长21.01%，达1.66亿元。股本股东变化股东户数变动近日凯赛生物披露，截至2026年3月31日公司股东户数为1.85万户，较12月31日增加4106.0户，增幅为28.48%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600003512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632401846","title":"每周股票复盘：凯赛生物（688065）现折价21.99%大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2632401846","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632401846?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:52","pubTimestamp":1777668730,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，凯赛生物报收于48.11元，较上周的47.42元上涨1.46%。本周，凯赛生物4月30日盘中最高价报49.96元。业绩披露要点：凯赛生物2026年一季度归母净利润1.66亿元，同比增长21.01%。交易信息汇总4月29日凯赛生物现1笔折价21.99%的大宗交易，合计成交499.02万元。股本股东变化股东户数变动近日凯赛生物披露，截至2026年3月31日公司股东户数为1.85万户，较12月31日增加4106.0户，增幅为28.48%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632266049","title":"凯赛生物（688065）2026年一季报简析：营收净利润同比双双增长，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2632266049","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632266049?lang=zh_cn&edition=full","pubTime":"2026-05-01 06:45","pubTimestamp":1777589148,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期凯赛生物发布2026年一季报。截至本报告期末，公司营业总收入8.75亿元，同比上升12.73%，归母净利润1.66亿元，同比上升21.01%。本报告期凯赛生物三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达131.97%。然而去年的净利率为16.07%，算上全部成本后，公司产品或服务的附加值高。持有凯赛生物最多的基金为科创新材料ETF博时，目前规模为2.02亿元，最新净值1.0215，较上一交易日下跌0.44%，近一年上涨75.2%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050100007130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782254820418,"stockEarnings":[{"period":"1week","weight":0.1721},{"period":"1month","weight":0.1735},{"period":"3month","weight":0.0427},{"period":"6month","weight":0.0343},{"period":"1year","weight":0.1046},{"period":"ytd","weight":0.0241}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0016},{"period":"3month","weight":0.0444},{"period":"6month","weight":0.037},{"period":"1year","weight":0.2143},{"period":"ytd","weight":0.0346}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海凯赛生物技术股份有限公司","boardCode":"AI0028","boardName":"化学纤维制造业","stockholders":"18523人(较上一季度增加28.48%)","perCapita":"31494股","listingDate":"2020-08-12","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路1690号5幢4楼","registeredCapital":"72128万元","survey":" 上海凯赛生物技术股份有限公司的主营业务是新型生物基材料的研发、生产及销售。公司的主要产品是系列生物法长链二元酸（DC10-DC18）、生物基戊二胺、系列生物基聚酰胺、生物基连续纤维热塑型复合材料（Bio-PPACFRT）。截至报告期末，公司拥有434项发明专利在内的562项专利，被认定为“国家企业技术中心”、“国家级第三批专精特新‘小巨人’企业”、“国家知识产权局优势企业”、“国家绿色工厂”、“国家制造业单项冠军企业”。","listedPrice":133.45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯赛生物(688065)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯赛生物(688065)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯赛生物,688065,凯赛生物股票,凯赛生物股票老虎,凯赛生物股票老虎国际,凯赛生物行情,凯赛生物股票行情,凯赛生物股价,凯赛生物股市,凯赛生物股票价格,凯赛生物股票交易,凯赛生物股票购买,凯赛生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯赛生物(688065)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯赛生物(688065)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}